Yale University, School of Medicine, Department of Psychiatry and VA Connecticut Healthcare System, West Haven, CT 06516, USA.
Am J Drug Alcohol Abuse. 2009;35(6):412-6. doi: 10.3109/00952990903383961.
Although preclinical studies support the contribution of the noradrenergic system activation in mediating the acute effects of amphetamines, these findings have not been followed up in clinical studies.
To examine the effects of atomoxetine, a norepinephrine transporter inhibitor, on subjective, physiological, and plasma cortisol responses to dextroamphetamine in 10 healthy volunteers.
Subjects were randomly assigned to a sequence of atomoxetine (40 mg/day) or placebo treatments each lasting for 4 days. On Day 4 of each treatment period, responses to a single 20 mg/70 kg dose of dextroamphetamine were assessed.
Atomoxetine treatment attenuated dextroamphetamine-induced increases in systolic and diastolic blood pressure and plasma cortisol as well as the self-report ratings of "stimulated," "high," and "good drug effects."
These findings are consistent with previous preclinical studies supporting the role of the noradrenergic system in mediating acute amphetamine responses.
Atomoxetine's capacity to attenuate some of the physiological and subjective responses to dextroamphetamine supports its potential use for stimulant addiction.
尽管临床前研究支持去甲肾上腺素能系统的激活在介导安非他命的急性作用，但这些发现尚未在临床研究中得到证实。
在 10 名健康志愿者中，检查去甲肾上腺素转运体抑制剂托莫西汀对右旋苯丙胺引起的主观、生理和血浆皮质醇反应的影响。
受试者随机分为托莫西汀（40mg/天）或安慰剂治疗组，每组持续 4 天。在每个治疗期的第 4 天，评估单次 20mg/70kg 剂量的右旋苯丙胺的反应。
托莫西汀治疗可减弱右旋苯丙胺引起的收缩压和舒张压以及血浆皮质醇升高，以及自我报告的“兴奋”、“高”和“药物效果好”的评分。
这些发现与以前支持去甲肾上腺素能系统在介导急性安非他命反应中的作用的临床前研究一致。
托莫西汀减弱右旋苯丙胺某些生理和主观反应的能力支持其在治疗兴奋剂成瘾方面的潜在用途。
